Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial.

@article{Ruzicka2008EfficacyAS,
  title={Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial.},
  author={Thomas Ruzicka and Charles W. Lynde and Gregor B. E. Jemec and T. L. Diepgen and John Berth-Jones and Peter Jan Coenraads and Andrzej Kaszuba and R Bissonnette and Elina Varjonen and P{\'e}ter H{\'o}llo and Frederic Cambazard and Morad Lahfa and Peter Elsner and Filippa Nyberg and {\AA}ke Svensson and Thomas Christopher Brown and Martin Harsch and J{\"u}rgen Maares},
  journal={The British journal of dermatology},
  year={2008},
  volume={158 4},
  pages={808-17}
}
BACKGROUND Patients with severe chronic hand eczema (CHE) refractory to topical corticosteroids currently have limited treatment options suited for chronic use, and few controlled clinical studies have investigated new therapies in this setting. OBJECTIVES To assess the efficacy and safety of oral alitretinoin (9-cis retinoic acid) taken at 10 mg or 30 mg once daily for up to 24 weeks, compared with placebo control, in the treatment of severe CHE refractory to topical corticosteroids… CONTINUE READING
Highly Influential
This paper has highly influenced 13 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS